The global biopharmaceuticals manufacturing consumables testing market accounted for USD 0.523 billion in 2023 and is expected to reach USD 1.90 billion by 2034 with a CAGR of 12.46% during the forecast period 2024-2034. The market will grow due to factors such as growing demand for biopharmaceuticals, improvements in bioprocessing technologies, an emphasis on risk mitigation and quality assurance, the expansion of biopharmaceutical manufacturing facilities, and an increased focus on biologics and personalized medicine.
The demand for biopharmaceutical manufacturing consumables testing is driven by the increased desire for personalized medicine and the development of biologics, including gene treatments, cell-based therapies, and monoclonal antibodies. To ensure product quality and safety, these cutting-edge treatments frequently require unique production techniques and materials, which calls for stringent testing procedures. For instance, Charles River Laboratories International, Inc. enhanced its scientific capabilities in the biopharmaceutical services sector by announcing the acquisition of HarkerBIO, LLC in February 2022.
By type, the stability testing segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increasing emphasis on ensuring product quality, safety, and compliance throughout the product lifecycle, driving the demand for comprehensive stability testing services. For instance, in March 2022, Intertek Group plc announced that it will be acquiring SASTech LLC to expand its pharmaceutical and biopharmaceutical testing services. Additionally, the enzyme testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of enzymes in biopharmaceutical manufacturing processes, coupled with the need for precise and efficient testing methods to ensure enzyme activity and quality.
By raw material, the active pharmaceutical ingredients (API) testing segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increasing demand for stringent quality control measures and regulatory compliance throughout the API manufacturing process, driving the need for comprehensive testing services. For instance, in January 2022, Thermo Fisher Scientific announced that it was acquiring Mesa Biotech Inc. to boost its molecular diagnostics capabilities. Additionally, the formulation excipients testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing complexity in biopharmaceutical formulations and the rising emphasis on testing excipients for compatibility, stability, and safety.
By application, the pharma and biological segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increased investment in research and development of pharmaceuticals and biological products, driving demand for comprehensive testing services to ensure product quality and regulatory compliance. For instance, in September 2022, Pace Analytical Services purchased American Water Works Service Company, thereby increasing its capacity for environmental testing. Additionally, the medical devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for biopharmaceutical-related medical devices and the increasing need for testing to ensure their safety, efficacy, and compliance with regulatory standards.
By End-User, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increased outsourcing of manufacturing activities by pharmaceutical and biotechnology companies, driving demand for consumables testing services to maintain quality and regulatory compliance. For instance, in September 2022, Almac Group stated that it will be expanding its U.S. headquarters to include a larger facility in Pennsylvania, which would increase its ability to provide pharmaceutical and biopharmaceutical services. Additionally, the contract development and manufacturing organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing by biopharmaceutical companies and the rising demand for comprehensive testing services from contract development and manufacturing organizations to ensure product quality and regulatory compliance.
North American region is anticipated to have the highest revenue share during the forecast period owing to the dominance of key biopharmaceutical manufacturers, stringent regulatory standards, and high investment in research and development activities in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biopharmaceutical industry, increasing outsourcing trend, favorable regulatory environment, and growing investments in healthcare infrastructure and research and development in the Asia Pacific region. For instance, Agilent Technologies Inc. purchased cutting-edge artificial intelligence (AI) technology created by Virtual Control in February 2022.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The demand for biopharmaceutical manufacturing consumables testing is driven by the increased desire for personalized medicine and the development of biologics, including gene treatments, cell-based therapies, and monoclonal antibodies. To ensure product quality and safety, these cutting-edge treatments frequently require unique production techniques and materials, which calls for stringent testing procedures. For instance, Charles River Laboratories International, Inc. enhanced its scientific capabilities in the biopharmaceutical services sector by announcing the acquisition of HarkerBIO, LLC in February 2022.
By type, the stability testing segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increasing emphasis on ensuring product quality, safety, and compliance throughout the product lifecycle, driving the demand for comprehensive stability testing services. For instance, in March 2022, Intertek Group plc announced that it will be acquiring SASTech LLC to expand its pharmaceutical and biopharmaceutical testing services. Additionally, the enzyme testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of enzymes in biopharmaceutical manufacturing processes, coupled with the need for precise and efficient testing methods to ensure enzyme activity and quality.
By raw material, the active pharmaceutical ingredients (API) testing segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increasing demand for stringent quality control measures and regulatory compliance throughout the API manufacturing process, driving the need for comprehensive testing services. For instance, in January 2022, Thermo Fisher Scientific announced that it was acquiring Mesa Biotech Inc. to boost its molecular diagnostics capabilities. Additionally, the formulation excipients testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing complexity in biopharmaceutical formulations and the rising emphasis on testing excipients for compatibility, stability, and safety.
By application, the pharma and biological segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increased investment in research and development of pharmaceuticals and biological products, driving demand for comprehensive testing services to ensure product quality and regulatory compliance. For instance, in September 2022, Pace Analytical Services purchased American Water Works Service Company, thereby increasing its capacity for environmental testing. Additionally, the medical devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for biopharmaceutical-related medical devices and the increasing need for testing to ensure their safety, efficacy, and compliance with regulatory standards.
By End-User, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global biopharmaceuticals manufacturing consumables testing market in 2023 owing to the increased outsourcing of manufacturing activities by pharmaceutical and biotechnology companies, driving demand for consumables testing services to maintain quality and regulatory compliance. For instance, in September 2022, Almac Group stated that it will be expanding its U.S. headquarters to include a larger facility in Pennsylvania, which would increase its ability to provide pharmaceutical and biopharmaceutical services. Additionally, the contract development and manufacturing organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of outsourcing by biopharmaceutical companies and the rising demand for comprehensive testing services from contract development and manufacturing organizations to ensure product quality and regulatory compliance.
North American region is anticipated to have the highest revenue share during the forecast period owing to the dominance of key biopharmaceutical manufacturers, stringent regulatory standards, and high investment in research and development activities in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biopharmaceutical industry, increasing outsourcing trend, favorable regulatory environment, and growing investments in healthcare infrastructure and research and development in the Asia Pacific region. For instance, Agilent Technologies Inc. purchased cutting-edge artificial intelligence (AI) technology created by Virtual Control in February 2022.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Raw Material, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Biopharmaceuticals Manufacturing Consumables Testing Market Report 2023 - 2034
Biopharmaceuticals Manufacturing Consumables Testing Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Chemical Analysis Testing
- Enzyme Testing
- Stability Testing
- Sterility Testing
- Others
Biopharmaceuticals Manufacturing Consumables Testing Market Analysis & Forecast by Raw Material 2023 - 2034 (Revenue USD Bn)
- Formulation Excipients
- Active Pharmaceutical Ingredients (API)
- Compendial methods (USP/EP/JP) Based
- Vendor Qualification Program Support
Biopharmaceuticals Manufacturing Consumables Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Pharma and Biological
- Medical Devices
- Others
Biopharmaceuticals Manufacturing Consumables Testing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Development and Manufacturing Organizations (CDMOs)
- Others
Biopharmaceuticals Manufacturing Consumables Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biopharmaceuticals Manufacturing Consumables Testing Market: Type Estimates & Trend Analysis
8. Biopharmaceuticals Manufacturing Consumables Testing Market: Raw Material Estimates & Trend Analysis
9. Biopharmaceuticals Manufacturing Consumables Testing Market: Application Estimates & Trend Analysis
10. Biopharmaceuticals Manufacturing Consumables Testing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Biopharmaceuticals Manufacturing Consumables Testing Market
13. Europe Global Biopharmaceuticals Manufacturing Consumables Testing Market
14. Asia Pacific Global Biopharmaceuticals Manufacturing Consumables Testing Market
15. Latin America Global Biopharmaceuticals Manufacturing Consumables Testing Market
16. MEA Global Biopharmaceuticals Manufacturing Consumables Testing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Charles River Laboratories International Inc.
- Eurofins Scientific
- SGS SA
- Avomeen Analytical Services
- Toxikon Corporation
- WuXi AppTec
- Nelson Laboratories LLC
- Pace Analytical Services LLC
- Intertek Group plc
- BioReliance Corporation (a subsidiary of Merck KGaA)
- Almac Group
- PPD Inc.
- Exova Group plc.
